Micofenolato De Mofetilo Kern Pharma

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetilo Kern Pharma, is an immunosuppressant (antimetabolite) presented as an oral formulation for oral use. It is employed to prevent acute rejection in solid organ transplantation and to treat certain autoimmune kidney disorders such as lupus nephritis.

GNH USA supplies Micofenolato De Mofetilo Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil acts on the immune system to inhibit lymphocyte proliferation, making it useful in several transplant‑related and autoimmune conditions. - Prevention of acute organ transplant rejection: lowers the risk of graft loss in kidney, heart, liver and other solid organ transplants. - Lupus nephritis: helps control renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Prophylaxis of graft‑versus‑host disease: reduces incidence and severity of GVHD after hematopoietic stem cell transplantation.

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, may lead to dehydration. - Headache: transient cranial discomfort. - Upper respiratory tract infection: increased susceptibility to common colds. - Abdominal pain: cramping or discomfort in the stomach area.

Serious or Rare Side Effects: - Bone marrow suppression: leukopenia, anemia or thrombocytopenia requiring laboratory monitoring. - Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Malignancies: increased risk of lymphoproliferative disorders with long‑term use. - Progressive multifocal leukoencephalopathy: rare but potentially fatal brain infection.

Patients receiving Mycophenolate Mofetil should be observed for safety concerns and appropriate laboratory monitoring. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust therapy in patients with impaired kidney function. - Screen for infections: evaluate for latent tuberculosis, hepatitis B/C before initiating treatment. - Avoid in pregnancy: drug is teratogenic (Category D) and should not be used by pregnant women. - Contraception required: use effective birth control during treatment and for at least six weeks after discontinuation. - Store at below 25°C: keep in the original container, protect from moisture and light.

Mycophenolate Mofetil can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Live vaccines: increased risk of vaccine‑derived infection. - Other antimetabolites (e.g., azathioprine): additive bone‑marrow suppression. - Strong CYP inducers (rifampin, carbamazepine): markedly reduce mycophenolate exposure. - Antacids containing aluminum or magnesium: may decrease absorption of mycophenolic acid. - High‑dose steroids: can amplify immunosuppressive effect.

Moderate Interactions (Monitor Closely): - Calcineurin inhibitors (cyclosporine, tacrolimus): may raise mycophenolate levels, requiring dose adjustment. - Warfarin: potential enhancement of anticoagulant effect, monitor INR. - ACE inhibitors or ARBs: monitor renal function and potassium levels when combined.